Allogene Therapeutics, Inc. Aktie News

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Citi's SMID Call Series 2025 October 2, 2025 1:00 PM EDT Company Participants Zachary Roberts - Executive VP of Research & Development and Chief Medical Officer Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Citigroup Inc., Research Division Good afternoon, and thank you for joining. I'...

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will participate in one upcoming investor conference in September.

I maintain a 'Buy' rating on Allogene Therapeutics, as their diverse allogeneic cell therapy pipeline shows encouraging early data and pivotal trials are progressing. ALLO's financial position remains solid, with over $300 million in liquidity, sufficient to reach key data catalysts through 2027 despite brisk cash burn. The upcoming ALPHA3 futility analysis in 1H 2026 is a critical catalyst; po...

Allogene Therapeutics, Inc. (NASDAQ:ALLO ) Q2 2025 Earnings Conference Call August 13, 2025 5:00 PM ET Company Participants Christine Cassiano - Executive VP, Chief Corporate Affairs & Brand Strategy Officer David D. Chang - Co-Founder, President, CEO & Director Geoffrey M.

SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today provided corporate updates and reported financial results for the quarter ended June 30, 2025.

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it will report the second quarter 2025 financial results and provide a business update on August 13, 2025, after the close of ...

SOUTH SAN FRANCISCO, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today announced that it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study e...

SOUTH SAN FRANCISCO, Calif., June 01, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, presented updated data from the Phase 1 TRAVERSE study of ALLO-316 in renal cell carcinoma (RCC) during an oral presentation at the 2025 ASCO Annua...